Micro RNA-21 expression levels in invasive breast carcinoma with a non-invasive component

Archives of Biological Sciences

Volumn 67, Issue 4, 2015, Pages 1285-1295

  Petrović, Nina ^a   Jovanović Ćupić, Snežana ^a   Brajušković, Goran ^a   Lukić, Silvana ^b   Roganović, Jelena ^a   Krajnović, Milena ^a   Mandušić, Vesna ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Invasive ductal carcinoma with non invasive component (IDC DCIS); miR 21 expression levels; The difference between IDC DCIS and IDC

Indexed keywords

EID: 84951790728     PISSN: 03544664     EISSN: None     Source Type: Journal    
DOI: 10.2298/ABS150327105P     Document Type: Article

References (38)

1. Allinen, M., Beroukhim, R., Cai L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., Schnitt, S., Sellers, W.R. and K. Polyak (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6, 17-32.
2. Brem, R. F., Fishman M. and J.A. Rapelyea (2007). Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging and magnetic resonance imaging: A comparative study. Acad. Radiol. 14, 945-950.
3. Buscaglia, L. E. B. and Y. Li (2011). Apoptosis and the target genes of miR-21. Chin. J. Cancer. 30, 371-380.
4. Castro, N. P., Osório, C. A. B. T., Torres, C., Bastos, E.P., Mourao-Neto, M., Soares, F.A., Brentani, H.P. and D.M. Carraro (2008). Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10, R87.
5. Chagpar, A. B., McMasters, K. M., Sahoo, S. and M. J. Edards (2009). Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? Surgery. 146, 561-568.
6. Daniel, A. R., Hagan, C. R. and C.A. Lange (2011). Progesterone receptor action: defining a role in breast cancer. Expert. Rev. Endocrinol. Metab. 6, 359-369.
7. Di Palma, S., Collins, N, Faulkes, C., Ping, B., Ferns, G., Haagsma, B., Layer, G., Kissin, M.W. and M.G. Cook (2006). Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J. Clin. Pathol. 60, 1067-1068.
8. Dieterich, M., Hartwig, F., Stubert, J., Klocking, S., Kundt, G., Stengel, B., Reimer, T. and B.L. Gerber (2014). Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. The Breast. 23, 346-351.
9. Farabegoli, F., Champeme, M. H., Bieche, I., Santini, D., Ceccarelli, C., Derenzini, M. and R. Lidereau (2002). Genetic pathways in the evolution of breast ductal carcinoma in situ. J. Pathol. 196, 280-286.
10. Gerdes, J., Li, L., Schlueter, C., Duchrow, M., Wohlenberg, C. Gerlach, C., Stahmer, I., Kloth, S., Brandt, E. and H. D. Flad (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Path. 138, 867-873.
11. Hanahan, D., and Weinberg, A. R (2011). Hallmarks of Cancer: The Next Generation. Cell. 144, 646-674.
12. Huang, G.L., Zheng, X.H., Guo, G.L., Huang, K.T., Yang, K.Y., Shen, X., You, J. and X.Q. Hu (2009). Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol. Rep. 21, 673-679.
13. Huang, T. H., Wu, F., Loeb, G.B., Hsu, R., Heidersbash, A., Brincat, A., Horiuchi, D., Lebbink, R.J., Mo, Y.Y., Goga A. and M.T. McManus (2009). Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion. J. Biol. Chem. 284, 18515-18524.
14. Iakovlev, V. V., Arneson, N. C. R., Wong, V., Wang, C., Leung, S., Iakovleva G., Warren, K., Pintille, M. and S.J. Done (2008). Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a Calibrated a CGH study. Clin. Cancer Res. 14, 4446-4454.
15. Kim, Y. J., Hwang, S. J., Bae, J.C. and J.S. Jung (2009). miR-21 Regulates Adipogenic Differentiation Through the Modulation of TGF-β Signaling in Mesenchymal Stem Cells Derived from Human Adipose Tissue. Stem Cells. 27, 3093-102.
16. Leake, R. (2000). Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J. Clin. Pathol. 53, 634-635.
17. Ma, H., Bernstein, L., Ross, R.K. and G. Ursin (2006). Hormonerelated risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res. 8, R39.
18. Mattie, M.D., Benz, C.C., Bowers, J., Sensinger, K., Wong, L., Scott, G.K., Fedele, V., Ginzinger, D., Getts, R. and C. Haqq (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer. 5, 24.
19. Pan, X., Wang, Z-X. and R. Wang (2010). MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol. Ther. 10, 1224-1232.
20. Patla, A., Rudnicka-Sosin, L., Pawlega, J. and J. Stachura (2002). Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ. Pol. J. Pathol. 53, 25-27.
21. Petrović, N., Mandušić, V., Dimitrijević, B., Roganović, J. , Lukić, S., Todorović, L. and B. Stanojević (2014). Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia. Med. Oncol. 31, 1-9.
22. Petrović, N., Mandušić, V., Stanojević B., Lukić, S., Todorović, L., Roganović, J. and B. Dimitrijević (2014). The difference in miR-21 expression levels between invasive and noninvasive breast cancers emphasizes its role in breast cancer invasion. Med. Oncol. 31, 1-9.
23. Pinder, S. E. and I. O. Ellis (2003). Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)-current definitions and classification. Breast Cancer Res. 5, 254.
24. Polyak, K. (2007). Breast cancer: origins and evolution. J Clin Invest. 117(11), 3155-3163.
25. Polyak, K. and M. Hu (2005). Do myoepithelial cells hold the key for breast tumor progression? J. Mammary Gland Biol. Neoplasia. 10, 231-247.
26. Qi, L., Bart J., Tan L., Platteel I., Sluis, T., Huitema, S., Harms, G., Fu, L., Hollema H. and A. Berg (2009). Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 9, 163.
27. Singletary, S. E. (2002). Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J. Clin. Oncol. 20, 3628-3636.
28. Soliman, A. A., Wojcinski, S. and F. Degenhardt (2012). The effect of accompanying in situ ductal carcinoma on accuracy of measuring malignant breast tumor size using B-Mode Ultrasonography and Real-Time Sonoelastography. Int. J. Breast Cancer. 2012, 1-5.
29. Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., Yheng, Z. and X. Song (2010). MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J. Exp. Clin. Cancer Res. 29, 29.
30. Tang, J., Ahmad, A. and F.H. Sarkar (2012). The role of MicroRNAs in breast cancer migration, invasion and metastasis. Int. J. Mol. Sci. 13, 13414-13437.
31. Velds, A., Halfwerk, J. B. G., Kreike, B., Peterse, J.L. and M.J. van de Vijver (2006). Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 8, R61.
32. Verkooijen, H. M., Fioretta, G. R., Vlastos, G., Morabia, A., Schubert, H., Sappino, A.P., Pelte, M.F., Schefer, P., Kurtz, J. and C. Bouchardz (2003). Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int. J. Cancer. 104, 778-781.
33. Virnig, B. A., Tuttle, T. M., Shamlyan, T. and Kane, R.L. et al., (2010). Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment and Outcomes. J. Natl. Cancer Inst. 102, 170-178.
34. Wickramasinghe, N. S., Manavalan, T. T., Dougherty, S.M., Riggis, K.A., Li, Y. and C.M. Klinge (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37, 2584-2595.
35. Wong, H., Lau, S., Yau, T., Cheung, P. and R.J. Epstein (2010). Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br. J. Cancer. 102, 1391-1396.
36. Yan, L. X., Huang, X.F., Shao, Q., Huang, M.Y., Deng, L., Wu, Q.L., Zeng, Y.X. and J.Y. Shao (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna. 14, 2348-2360.
37. Yan, L. X., Huang, X. F., Zhang, Y., Li, Y.Y., Liao, D.Z., Hou, J.H., Fu, J., Zeng, M.S., Yun, J.P., Wu, Q.L., Zeng, Y.X. and J.Y. Shao (2011). Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 13, R2.
38. Yang, Y., Chaerkady, R., Beer, M.A, Mendell, J.T. and A. Pandey (2009). Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics. 9, 1374-1384.